It was found that shikonin inhibits pathological lymphangiogenesis, such as tumor induced lymphangiogenesis, by down regulating the expression of VEGF-C and VEGFR-3 genes in lymphangioendothelial cells (Prangsaengtong et al., 2018). This evidence concerns the gene FLT4 and neoplasm.